Dr Martin Welschof | Chief Executive Officer
Opsona Therapeutics Ltd

Dr Martin Welschof, Chief Executive Officer, Opsona Therapeutics Ltd

Before joining Opsona in Feb 2012, Martin was the Managing Director and Co-founder of Affitech A/S, a biopharmaceutical company focused on the discovery and development of human antibodies. Under his leadership Affitech AS was transformed through a reverse merger in 2009 with Pharmexa A/S a public Danish company and listed on the Copenhagen stock exchange. In 2010 he was one of the key resources concerning the implementation of a strategic partnership with the Russian Pharmaceutical IBC Generium as well as securing strategic investment from major Russian pharma players.
 
Prior to Affitech Martin was the Director of Technology at Axaron Bioscience AG responsible for transcription analysis and functional genomics. During that time he worked at Axaron’s parent company, LYNX Therapeutics Inc., Hayward, California, where he contributed to the process development of LYNX massive parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS.
 
Martin Welschof did his post-doctoral training at the German Cancer Research Center's Department for Recombinant Antibody Technology and the University of Heidelberg's Department of Transplantation Immunology. He has a Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, Germany.

Appearances:



WIC 2017 Day 1, Tuesday 31st October 2017 @ 16:30

OPN-305, a first in class toll like receptor 2 (TLR2) antibody inhibitor

  • TLR2 is a key structure of the innate immune system and one of the main initiators and propagators of inflammation
  • OPN-305 is a first in class TLR2 antagonist and anti-inflammatory compound with a unique mode of action
  • The TLR2 system is associated and involved with a number of major human diseases:
  • (cancer, ischemia reperfusion injury, and autoimmune diseases, among others)
  • Pre-clinical and clinical data supports a strong value proposition in oncology
  • TLR2 seems to play a major role in the function of tumor dendritic and T regulatory cells pointing to an immune-modulatory role
 

back to speakers